On April 3, 2025, Boehringer Ingelheim, through its subsidiary NBE Therapeutics, inaugurated a new antibody-drug conjugate (ADC) R&D facility in Basel, Switzerland. The company is investing CHF 27 million to strengthen its oncology research capabilities, emphasizing its commitment to developing innovative, targeted cancer therapies.
The new site reinforces Boehringer’s presence in Switzerland’s biotech ecosystem and supports its broader ADC strategy, which includes a recent license agreement with Synaffix B.V., Amsterdam and a new research facility in Vienna. NBE Therapeutics focuses on developing next-generation ADCs, a targeted approach that delivers cancer-fighting agents directly to tumor cells while limiting effects on healthy tissue. ADCs combine the specificity of antibodies with the therapeutic activity of cytotoxics, offering a promising option for cancer treatment to improve the quality of life for patients
The Basel facility will house about 50 scientists and includes 1,826 m² of lab and office space. It’s designed to meet top sustainability standards, receiving the DGNB Gold certification.
Bron: Boehringer Ingelheim